Waking Up to REMS (Part 3): Redefining Marketing
This article was originally published in RPM Report
Executive Summary
FDA's new post-marketing safety authorities place unprecedented burdens on pharmaceutical marketers. But they do something else: redefine a favorite target of industry critics as a regulatory requirement rather than a suspicious activity.
You may also be interested in...
FDA Panelist Questions Marketing Benefits From Soliris REMS
Cleveland Clinic hematologist suggests eculizumab risk management plan provides Alexion with an opportunity for direct-to-consumer marketing.
Declaring Victory: How FDA Releases REMS
There is a new category of FDA action letter: a REMS release. Dozens of sponsors of “MedGuide-only” REMS received them after an FDA policy change. But now, FDA is issuing them regularly to sponsors whose communication plans have met their goals – or at least run their course.
FDAAA Impact Analysis (Year 3): REMS R.I.P.? Not Yet
FDA’s reconsideration of its new Risk Evaluation & Mitigation Strategy authority put the brakes on use of the new post-marketing safety tools as 2011 began, and a formal decision not to require REMS for all products with mandatory MedGuides means a significant step down in use of REMS in the future. But that doesn’t mean REMS won’t be routine in the future.